Causes of Progression of Renal Disease

  • S. Klahr
  • K. Harris
Part of the Topics in Renal Medicine book series (TIRM, volume 7)

Abstract

In kidney diseases characterized by irreversible injury, it appears that once a critical level of renal functional deterioration is reached, progression to end-stage disease occurs frequently, even if the initiating event or condition is resolved or eradicated. The immunologic mechanisms and the mediators of kidney tissue damage that they induce may be responsible for initiating most renal diseases, but certain clinical and experimental observations suggest that the rate of progression of these diseases is influenced by several non-immuno-logical factors. Studies on the mechanisms underlying the progression of renal disease have utilized experimental animal models. The most widely used experimental model has utilized the ablation of renal mass in rats. Animals with subtotal renal ablation develop proteinuria, hypertension, and glomerulosclerosis in the viable portion of the remnant kidney. The pathogenesis of these abnormalities has not been completely elucidated. Hypertrophy of the residual renal mass occurs after ablation. This hypertrophy, as mentioned, is accompanied by a marked increase in plasma flow per nephron and in single-nephron glomerular filtration rate (SNGFR). Structural alterations occur in all three glomerular cell types. Three weeks after renal ablation, adhesion of epithelial cells to Bowman’s capsule may be seen in severely involved glomeruli. In some areas, epithelial cells are detached from their underlying basement membrane. There is a prominent increase in mesangial cells and mesangial matrix.

Keywords

Phosphorus Sodium Chloride Heparin Angiotensin Bicarbonate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brenner BM: (1985) Nephron adaptation to renal injury or ablation. Am J Physiol 249: F324-F337.PubMedGoogle Scholar
  2. 2.
    Purkerson ML, Joist JH, Yates J, Valdes A, Morrison A, Klahr S: (1985) Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation. Proc Natl Acad Sci USA 82:193.PubMedCrossRefGoogle Scholar
  3. 3.
    Anderson S, Rennke HG, Brenner BM: (1986) Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993–2000.PubMedCrossRefGoogle Scholar
  4. 4.
    Purkerson ML, Hoffsten PE, Klahr S: (1976) Pathogenesis of the glomerulopathy associated with renal infarction in rats. Kidney Int 9:407–417.PubMedCrossRefGoogle Scholar
  5. 5.
    Purkerson ML, Joist JH, Greenberg JM, Kay D, Hoffsten PE, Klahr S: (1982) Inhibition by anticoagulant drugs of the progressive hypertension and uremia associated with renal infarction in rats. Thrombosis Res 26:277.CrossRefGoogle Scholar
  6. 6.
    Nathan CF: (1987) Secretory products of macrophages. J Clin Invest 79:319–326.PubMedCrossRefGoogle Scholar
  7. 7.
    Schainuck LI, Striker GE, Cutler RE, Benditt EP: (1970) Structural-functional correlations in renal disease. II. The correlations. Hum Pathol 1:631–641.PubMedCrossRefGoogle Scholar
  8. 8.
    Bohle A, Christ H, Grund KE, Mackensen S: (1979) The role of the interstitium of the renal cortex in renal disease. Contr Nephrol 16:109–114.Google Scholar
  9. 9.
    Nath KA, Hostetter MK, Hostetter TH: (1985) Pathophysiology of chronic tubulo-interstitial disease in rats. Interaction of dietary acid load, ammonia, and complement component C3. J Clin Invest 76:667–675.PubMedCrossRefGoogle Scholar
  10. 10.
    Isenman DE, Keils DIC, Cooper NR, Muller-Ederhard HJ, Pangburn MK: (1981) Nucleo-philic modification of human complement protein C3: Correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry 20:4458–4467.PubMedCrossRefGoogle Scholar
  11. 11.
    Pangburn MK, Schreiber RD, Muller-Eberhard HJ: (1981) Formation of the initial C3 convertase of the alternative complement pathway. J Exp Med 154:856–867.PubMedCrossRefGoogle Scholar
  12. 12.
    Klahr S, Buerkert J, Purkerson ML: (1983) The role of dietary factors in the progression of chronic renal disease. Kidney Int 24:579–587.PubMedCrossRefGoogle Scholar
  13. 13.
    Lumlergul D, Burke TJ, Gillum DM, et al.: (1986) Phosphate depletion arrests progression of chronic renal failure independent of protein intake. Kidney Int 29:658–666.CrossRefGoogle Scholar
  14. 14.
    Barcelli UO, Weiss M, Pollak VE: (1982) Effects of a dietary prostaglandin precursor on the progression of experimentally induced chronic renal failure. J Lab Clin Med 100:786–797.PubMedGoogle Scholar
  15. 15.
    Heifets M, Morrissey JJ, Purkerson ML, Morrison AR, Klahr S: (1987) Effect of dietary lipids on renal function in rats with subtotal nephrectomy. Kidney Int 32:335–341.PubMedCrossRefGoogle Scholar
  16. 16.
    Raij L, Chou X, Owens R, Wrigley B: (1985) Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, re-serpine and hydrochlorothiazide in an experimental model. Am J Med 79 (Suppl 3c):37–45.PubMedCrossRefGoogle Scholar
  17. 17.
    Keane WF, Kasiske BL, O’Donnell MP: (1988) Hyperlipidemia and the progression of renal disease. Am J Clin Nutr, 47:157–160.PubMedGoogle Scholar
  18. 18.
    Heifets M, Davis TA, Tegtmeyer E, Klahr S. Exercise training ameliorates progressive renal disease in rats with subtotal nephrectomy. Kidney Int, 32:815–820.Google Scholar
  19. 19.
    Klahr S, Heifets M, Purkerson ML: (1986) The influence of anticoagulation on the progression of experimental renal disease. In: Mitch WE, Brenner BM, Stein JH (eds). The Progressive Nature of Renal Disease. New York: Churchill Livingstone, pp 45–64.Google Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1989

Authors and Affiliations

  • S. Klahr
  • K. Harris

There are no affiliations available

Personalised recommendations